Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine

Emergent BioSolutions (EBS) signed an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract for a maximum value of up to $235.8 million with the U.S. Department of Defense (DoD) to supply its anthrax vaccine BioThrax.The vaccine is intended for use by all branches of the United States military as pre-exposure prophylaxis (PrEP) for anthrax disease.The procurement contract consists of a five-year base agreement ending on Sep 30, 2028, with an option to extend the contract for an additional fiv ...